Objective: This study aims to comprehensively analyze the factors influencing the efficacy of bone marrow platelet-rich plasma (BMPRP) therapy in patients with type 2 diabetes mellitus. Methods: In this clinical investigation, autologous bone marrow was harvested from participants, followed by the isolation of BMPRP. Patients then underwent ultrasound-guided infusion of BMPRP directly into the pancreas. The follow-up period for evaluating treatment outcomes spanned one year, during which various factors potentially affecting the therapeutic effects were systematically analyzed. Results: A total of 49 patients diagnosed with type 2 diabetes mellitus received BMPRP pancreatic infusion as a treatment modality. Among these patients, 32 demonstrated a positive response to the therapy, while 17 experienced no significant improvement. Notably, in the effective treatment group, fasting blood glucose levels exhibited a significant reduction after one month of intervention. Additionally, glycosylated hemoglobin (HbA1c) levels showed a substantial decrease at the three-month mark, and a gradual decline in insulin dosage requirements was observed over time. In contrast, changes in C-peptide levels were not pronounced. Analysis of the ineffective treatment group revealed that these patients often had obesity, demonstrated minimal physical activity, and did not adhere to dietary recommendations for carbohydrate control. Conclusion: The findings suggest that BMPRP pancreatic infusion can improve pancreatic function and glycemic control in type 2 diabetes patients. However, for optimal outcomes, it is crucial to combine this therapy with a regimen that includes regular exercise and strict management of carbohydrate intake. This multifaceted approach promises to enhance the effectiveness of BMPRP therapy and contribute to better overall management of type 2 diabetes.
| Published in | American Journal of Bioscience and Bioengineering (Volume 12, Issue 6) |
| DOI | 10.11648/j.bio.20241206.14 |
| Page(s) | 128-134 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Bone Marrow Platelet-rich Plasma, Ultrasound-guided, Type 2 Diabetes
| [1] | Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020; 369: m997. |
| [2] | Hu YM, Zhao LH, Zhang XL, et al. Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients. Endocrine. 2018; 60(2): 292-300. |
| [3] | Wang X, Zhao X, Dorje T, et al. Glycemic variability predicts cardiovascular complications in acute myocardial infarction patients with type 2 diabetes mellitus. Int J Cardiol. 2014; 172(2): 498-500. |
| [4] | Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008; 57(5): 1349-1354. |
| [5] | Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42(8): 1593-1603. |
| [6] | Saboo B, Kesavadev J, Shankar A, et al. Time-in-range as a target in type 2 diabetes: an urgent need. Heliyon. 2021; 7(1): e05967. |
| [7] | Lu J, Wang C, Shen Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021; 44(2): 549-555. |
| [8] | Liu X, Zheng P, Wang X, et al. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther. 2014; 5(2): 57. |
| [9] | Kong D, Zhuang X, Wang D, et al. Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. Clin Lab. 2014; 60(12): 1969-1976. |
| [10] | Guan LX, Guan H, Li HB, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015; 9(5): 1623-1630. |
| [11] | Zang L, Li Y, Hao H, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022; 13(1): 180. |
| [12] | Hammer MJ, Casper C, Gooley TA, et al. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009; 15(3): 344-351. |
| [13] | Storey S, Von Ah D. Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: a review of the literature. Oncol Nurs Forum. 2012; 39(5): 458-465. |
| [14] | Sopfe J, Pyle L, Keating AK, et al. Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients. Blood Adv. 2019; 3(3): 350-359. |
| [15] | Araujo DB, Dantas JR, Silva KR, et al. Allogenic adipose tissue-derived stromal/stem cells and vitamin D supplementation in patients with recent-onset type 1 diabetes mellitus: a 3-month follow-up pilot study. Front Immunol. 2020; 11: 993. |
| [16] | Yin Y, Hao H, Cheng Y, et al. Human umbilical cord-derived mesenchymal stem cells direct macrophage polarization to alleviate pancreatic islets dysfunction in type 2 diabetic mice. Cell Death Dis. 2018; 9(7): 760. |
| [17] | Xie Z, Hao H, Tong C, et al. Human umbilical cord-derived mesenchymal stem cells elicit macrophages into an anti-inflammatory phenotype to alleviate insulin resistance in type 2 diabetic rats. Stem Cells. 2016; 34(3): 627-639. |
| [18] | UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837-853. |
| [19] | Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977-986. |
| [20] | Bergenstal RM, Gal RL, Connor CG, et al. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med. 2017; 167(2): 95-102. |
| [21] | Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017; 40(12): 1631-1640. |
| [22] | Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018; 41(11): 2370-2376. |
| [23] | Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006; 295(14): 1707-1708. |
| [24] | Horváth EM, Benko R, Kiss L, et al. Rapid “glycaemic swings” induce nitrosative stress, activate poly (ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia. 2009; 52(5): 952-961. |
| [25] | Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD (P) H-oxidase activation. Diabetes. 2003; 52(11): 2795-2804. |
| [26] | Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013; 50(3): 437-442. |
| [27] | Low S, Lim SC, Yeoh LY, et al. Effect of long-term glycemic variability on estimated glomerular filtration rate decline among patients with type 2 diabetes mellitus: insights from the Diabetic Nephropathy Cohort in Singapore. J Diabetes. 2017; 9(10): 908-919. |
| [28] | Zhang X, Yang X, Sun B, Zhu C. Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review. Commun Biol. 2021; 4(1): 1366. |
| [29] | Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011; 10: 19. |
| [30] | Zhang S, Chen L, Zhang G, et al. Umbilical cord-matrix stem cells induce the functional restoration of vascular endothelial cells and enhance skin wound healing in diabetic mice via the polarized macrophages [J] Stem Cell Res Ther. 2020 Jan 28; 11(1): 39. |
| [31] | Memon B, Abdelalim EM. Stem Cell Therapy for Diabetes: Beta Cells versus Pancreatic Progenitors [J] Cells. 2020 Jan 23; 9(2). pii: E283. |
| [32] | Du, Y. et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat. Med. 28, 272–282 (2022). |
| [33] | Pagliuca, F. W. et al. Generation of functional human pancreatic β cells in vitro. Cell 159, 428–439 (2014). |
| [34] | Rezania, A. et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat. Biotechnol. 32, 1121–1133 (2014). |
| [35] | Balboa, D. et al. Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells. Nat. Biotechnol. |
| [36] | Grapin-Botton, A. & Ludwig, B. Stem cell-derived β cells go in monkeys. Cell Stem Cell 29, 500–502 (2022). |
APA Style
Liu, B., Gao, X., Chen, Y., Zheng, R., Dong, Q., et al. (2024). Analysis of Clinical Data on the Treatment of Type 2 Diabetes with BMPRP. American Journal of Bioscience and Bioengineering, 12(6), 128-134. https://doi.org/10.11648/j.bio.20241206.14
ACS Style
Liu, B.; Gao, X.; Chen, Y.; Zheng, R.; Dong, Q., et al. Analysis of Clinical Data on the Treatment of Type 2 Diabetes with BMPRP. Am. J. BioSci. Bioeng. 2024, 12(6), 128-134. doi: 10.11648/j.bio.20241206.14
AMA Style
Liu B, Gao X, Chen Y, Zheng R, Dong Q, et al. Analysis of Clinical Data on the Treatment of Type 2 Diabetes with BMPRP. Am J BioSci Bioeng. 2024;12(6):128-134. doi: 10.11648/j.bio.20241206.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.bio.20241206.14,
author = {Baochi Liu and Xiong Gao and Yuanhuai Chen and Ruping Zheng and Qiqiang Dong and Jingbo Wang},
title = {Analysis of Clinical Data on the Treatment of Type 2 Diabetes with BMPRP
},
journal = {American Journal of Bioscience and Bioengineering},
volume = {12},
number = {6},
pages = {128-134},
doi = {10.11648/j.bio.20241206.14},
url = {https://doi.org/10.11648/j.bio.20241206.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bio.20241206.14},
abstract = {Objective: This study aims to comprehensively analyze the factors influencing the efficacy of bone marrow platelet-rich plasma (BMPRP) therapy in patients with type 2 diabetes mellitus. Methods: In this clinical investigation, autologous bone marrow was harvested from participants, followed by the isolation of BMPRP. Patients then underwent ultrasound-guided infusion of BMPRP directly into the pancreas. The follow-up period for evaluating treatment outcomes spanned one year, during which various factors potentially affecting the therapeutic effects were systematically analyzed. Results: A total of 49 patients diagnosed with type 2 diabetes mellitus received BMPRP pancreatic infusion as a treatment modality. Among these patients, 32 demonstrated a positive response to the therapy, while 17 experienced no significant improvement. Notably, in the effective treatment group, fasting blood glucose levels exhibited a significant reduction after one month of intervention. Additionally, glycosylated hemoglobin (HbA1c) levels showed a substantial decrease at the three-month mark, and a gradual decline in insulin dosage requirements was observed over time. In contrast, changes in C-peptide levels were not pronounced. Analysis of the ineffective treatment group revealed that these patients often had obesity, demonstrated minimal physical activity, and did not adhere to dietary recommendations for carbohydrate control. Conclusion: The findings suggest that BMPRP pancreatic infusion can improve pancreatic function and glycemic control in type 2 diabetes patients. However, for optimal outcomes, it is crucial to combine this therapy with a regimen that includes regular exercise and strict management of carbohydrate intake. This multifaceted approach promises to enhance the effectiveness of BMPRP therapy and contribute to better overall management of type 2 diabetes.
},
year = {2024}
}
TY - JOUR T1 - Analysis of Clinical Data on the Treatment of Type 2 Diabetes with BMPRP AU - Baochi Liu AU - Xiong Gao AU - Yuanhuai Chen AU - Ruping Zheng AU - Qiqiang Dong AU - Jingbo Wang Y1 - 2024/12/07 PY - 2024 N1 - https://doi.org/10.11648/j.bio.20241206.14 DO - 10.11648/j.bio.20241206.14 T2 - American Journal of Bioscience and Bioengineering JF - American Journal of Bioscience and Bioengineering JO - American Journal of Bioscience and Bioengineering SP - 128 EP - 134 PB - Science Publishing Group SN - 2328-5893 UR - https://doi.org/10.11648/j.bio.20241206.14 AB - Objective: This study aims to comprehensively analyze the factors influencing the efficacy of bone marrow platelet-rich plasma (BMPRP) therapy in patients with type 2 diabetes mellitus. Methods: In this clinical investigation, autologous bone marrow was harvested from participants, followed by the isolation of BMPRP. Patients then underwent ultrasound-guided infusion of BMPRP directly into the pancreas. The follow-up period for evaluating treatment outcomes spanned one year, during which various factors potentially affecting the therapeutic effects were systematically analyzed. Results: A total of 49 patients diagnosed with type 2 diabetes mellitus received BMPRP pancreatic infusion as a treatment modality. Among these patients, 32 demonstrated a positive response to the therapy, while 17 experienced no significant improvement. Notably, in the effective treatment group, fasting blood glucose levels exhibited a significant reduction after one month of intervention. Additionally, glycosylated hemoglobin (HbA1c) levels showed a substantial decrease at the three-month mark, and a gradual decline in insulin dosage requirements was observed over time. In contrast, changes in C-peptide levels were not pronounced. Analysis of the ineffective treatment group revealed that these patients often had obesity, demonstrated minimal physical activity, and did not adhere to dietary recommendations for carbohydrate control. Conclusion: The findings suggest that BMPRP pancreatic infusion can improve pancreatic function and glycemic control in type 2 diabetes patients. However, for optimal outcomes, it is crucial to combine this therapy with a regimen that includes regular exercise and strict management of carbohydrate intake. This multifaceted approach promises to enhance the effectiveness of BMPRP therapy and contribute to better overall management of type 2 diabetes. VL - 12 IS - 6 ER -
Zigong Hospital, Affiliated to Southwest Medical University, Zigong, China
Zigong Hospital, Affiliated to Southwest Medical University, Zigong, China
